Harbin Pharmaceutical Group Co., Ltd. Class A

Harbin Pharmaceutical Group Co., Ltd. Class A

SSSE:600664
4.85
CNY
-0.16
(-3.19%)
0.26EPS
29.92P/E
18.64BMarket Cap
Apr 14Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
7.43
6.68
6.29
5.74
4.72
4.37
4.24
4.3
5.17
5.64
6.26
6.43
6.18
6.36
Basic EPS, GAAP
0.07
0.1
0.23
0.32
0.16
0.14
0.02
-0.43
0.15
0.19
0.16
0.25
0.14
0.25
Free Cash Flow per Basic Share
-0.09
0.31
0.54
1.08
0.02
0.23
-0.12
-0.34
-0.1
0.22
0.35
0.27
0.11
- -
Dividend per Share
- -
0.06
0.76
0.03
0.53
0.55
- -
0.01
0.02
0.02
0.02
0.02
0.01
0.01
Book Value per Share
3.26
3.3
2.83
3.09
2.76
2.3
2.18
1.39
1.53
1.71
1.87
2.12
2.26
2.5
Tangible Book Value per Share
3.08
3.12
2.65
2.92
2.58
2.09
1.97
1.18
1.3
1.5
1.67
1.93
2.05
2.29
Basic Weighted Avg Shares
2,436
2,471
2,522
2,463
2,544
2,472
2,791
2,506
2,474
2,448
2,470
2,515
2,583
2,560
Sales/Revenue/Turnover
18,092
16,509
15,856
14,127
12,018
10,814
11,825
10,788
12,802
13,809
15,457
16,176
15,964
16,295
Operating Margin (%)
2.2
2.9
5.75
7.6
4.96
5.07
2.11
-5.35
4.62
4.78
4.92
6.02
4.58
5.95
Depreciation Expense
431
448
474
468
437
422
398
370
308
310
304
288
275
- -
Net Income, GAAP
169
247
580
788
407
346
56
-1,078
371
465
395
629
362
633
Effective Tax Rate (%)
54.38
46.06
21.84
19.89
29.51
31.32
60.31
- -
35
26.95
27.1
21.07
30.37
22.56
Profit Margin (%)
0.93
1.5
3.66
5.58
3.39
3.2
0.47
-9.99
2.9
3.37
2.56
3.89
2.27
3.89
Working Capital
4,152
3,795
2,749
3,990
3,430
2,110
1,238
444
878
1,558
2,153
2,874
3,230
3,929
LT Debt
59
53
49
49
48
39
37
71
96
77
64
67
62
61
Total Equity
8,729
8,770
7,483
8,298
7,482
6,281
5,943
3,989
4,420
4,947
5,423
6,089
6,462
7,095
Return on Invested Capital (%)
1.22
2.08
7.14
10.17
5.91
5.32
1.76
- -
7.03
7.66
6.97
9.76
5.55
- -
Return on Capital (%)
2.3
3.36
6.65
9.12
4.38
4.27
0.11
- -
6.37
6.95
4.97
8.11
4.55
- -
Return on Common Equity (%)
2.1
3.02
7.59
10.57
5.46
5.36
0.99
-24.12
10.13
11.38
8.73
12.48
6.55
- -

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
1,161
1,244
1,002
LT Borrowings
31
32
32
LT Finance Leases
28
39
30
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
2,519
2,519
2,519
Market Capitalization
8,865
7,530
18,637

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
11,038
11,055
11,326
Cash, Cash Equivalents & STI
3,182
3,385
3,266
Accounts Receivable, Net
4,838
4,794
5,001
Inventories
2,161
1,965
2,035
Total Current Liabilities
7,611
7,334
7,396
Payables & Accruals
- -
- -
- -
ST Debt
1,161
1,244
1,002
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-0.25%
10.15%
6.12%
Free Cash Flow
71.72%
-82.08%
-58.26%
Net Income, GAAP
-224.98%
-21.5%
-42.5%
Sales/Revenue/Turnover
0.65%
8.36%
-1.31%
Total Cash Common Dividend
155.23%
20.46%
-29.32%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
4,142
4,000
4,114
3,919
16,176
2025
4,174
3,950
- -
3,943
15,964
2026
4,175
4,120
4,057
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.07
0.07
0.07
0.05
0.25
2025
0.08
0.02
- -
0.01
0.14
2026
0.06
0.1
0.08
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
0.01
- -
0.02
2025
0.01
- -
- -
- -
0.01
2026
- -
- -
- -
- -
- -

Company Description

CEO
Chuan You Lu
Full Time Employees
10,039
Sector
Health technology
Industry
Pharmaceuticals: major
Address
No. 7, Qunli Avenue Harbin HL China 150070
IPO Date
Jun 29, 1993
Website
hayao.com
Business
Harbin Pharmaceutical Group Co., Ltd. (600664.SS) engages in the research, development, manufacturing, wholesale, and retail of pharmaceuticals primarily in China and internationally; the company operates across seven key business segments including antibiotics, small-molecule drug preparations, OTC and healthcare products, modern Chinese medicines, biopharmaceuticals, animal vaccines, and medicine circulation. It offers a broad portfolio of products such as zinc gluconate oral solutions, calcium iron zinc oral solutions, compound calcium gluconate oral solutions, Shuanghuanglian oral solutions, amoxicillin capsules, recombinant human erythropoietin injections, ibuprofen granules, iron vitamin B12 oral solutions, ceftriaxone sodium injections, pediatric acetaminophen granules, Jiananxi Vitapak nutrition packages, lacidipine tablets, roxatidine acetate hydrochloride injections, penicillin and cephalosporin antibiotic preparations, as well as treatments for respiratory, chronic, digestive, blood and hematopoietic, anti-tumor and immunomodulatory, anti-inflammatory and analgesic, anti-virus and anti-infection, cerebrovascular, and cardiovascular diseases, mineral and nutritional supplements, and traditional Chinese medicines; products are marketed under brands including Harbin Pharmaceutical, Sanjing, Gaizhonggai, Hutong, and Shiyitang. Founded in 1991 and headquartered at No. 7 Qunli Avenue, Daoli District, Harbin, Heilongjiang Province, China, the company maintains eight major production bases, holds 1,816 drug approvals and 74 health food approvals, employs over 10,000 staff, and extends operations to more than 50 countries with a focus on domestic pharmaceutical wholesale and retail alongside diversified activities in medical devices, medical aesthetics, biology, health technology, culture, science and technology, passenger transport, food, property, security, and pharmaceutical investments. Recent developments include the completion of its acquisition of substantially all assets of GNC Holdings Inc. in 2020 through subsidiary Harbin Pharmaceutical Group Holding Co., Ltd. for approximately $770 million to bolster its global health and wellness presence, a 2015 controlling stake acquisition in Wanbang Biopharmaceuticals to strengthen biopharmaceutical capabilities in diabetes and cardiovascular treatments, and a 2021 acquisition of Shenzhen Kexing Bioproducts Co., Ltd. to expand vaccine production; in 2025, a planned acquisition of a 20% stake was cancelled, while the company reported 2024 annual results and 2025 semi-annual revenue of RMB 8.125 billion alongside ongoing R&D investments supporting over 1,000 product varieties.